$ACET
Adicet Bio, Inc.

2022 Q2 Form 10-Q Financial Statement

#000095017022009690 Filed on May 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $0.00 $24.99M $5.468M
YoY Change -100.0% -727.89% 1.07%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.529M $6.801M $6.352M
YoY Change 29.93% 20.8% 25.04%
% of Gross Profit
Research & Development $16.18M $13.48M $13.46M
YoY Change 52.39% 14.82% 39.03%
% of Gross Profit
Depreciation & Amortization $405.0K $352.0K $365.0K
YoY Change -10.99% 6.67% 14.06%
% of Gross Profit
Operating Expenses $22.71M $20.28M $19.81M
YoY Change 45.18% 16.76% 34.21%
Operating Profit -$22.71M $4.706M
YoY Change 109.73% -122.04%
Interest Expense $307.0K $18.00K $12.00K
YoY Change 501.96% -64.0% -60.0%
% of Operating Profit 0.38%
Other Income/Expense, Net -$138.0K -$102.0K -$294.0K
YoY Change 122.58% 2450.0% -233.64%
Pretax Income -$22.54M $4.618M -$15.82M
YoY Change 106.18% -121.61% 73.89%
Income Tax $0.00 $0.00 -$11.00K
% Of Pretax Income 0.0%
Net Earnings -$22.54M $4.618M -$15.81M
YoY Change 107.65% -121.66% 76.48%
Net Earnings / Revenue 18.48% -289.19%
Basic Earnings Per Share -$0.56 $0.12
Diluted Earnings Per Share -$562.4K $0.10 -$465.8K
COMMON SHARES
Basic Shares Outstanding 40.00M 39.82M 31.96M
Diluted Shares Outstanding 40.08M 45.96M

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $260.6M $277.9M $277.5M
YoY Change 24.87% 24.38% 193.34%
Cash & Equivalents $260.6M $277.9M $277.5M
Short-Term Investments $0.00
Other Short-Term Assets $3.446M $45.00K $31.00K
YoY Change 823.86% -63.71% -86.46%
Inventory
Prepaid Expenses $1.128M $115.0K
Receivables $0.00 $0.00 $185.0K
Other Receivables $0.00 $0.00 $29.00K
Total Short-Term Assets $264.1M $281.5M $282.4M
YoY Change 22.09% 22.89% 181.49%
LONG-TERM ASSETS
Property, Plant & Equipment $44.57M $17.74M $14.64M
YoY Change 291.09% 468.1% 424.84%
Goodwill $19.46M $19.46M
YoY Change -2.02% -3.12%
Intangibles $0.00
YoY Change
Long-Term Investments $0.00
YoY Change
Other Assets $1.789M $1.858M $1.887M
YoY Change -10.64% -11.48% 2.72%
Total Long-Term Assets $65.82M $58.92M $56.50M
YoY Change 25.42% 11.22% 5.61%
TOTAL ASSETS
Total Short-Term Assets $264.1M $281.5M $282.4M
Total Long-Term Assets $65.82M $58.92M $56.50M
Total Assets $329.9M $340.5M $338.9M
YoY Change 22.74% 20.7% 120.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.146M $3.465M $3.263M
YoY Change 79.02% 98.23% 110.24%
Accrued Expenses $12.25M $6.936M $8.249M
YoY Change 123.41% 26.11% 19.55%
Deferred Revenue $0.00 $4.805M
YoY Change -100.0% -65.63%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.40M $10.40M $16.32M
YoY Change -21.72% -58.7% -27.41%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $20.24M $115.0K $115.0K
YoY Change 3.84% -99.44%
Total Long-Term Liabilities $20.24M $115.0K $115.0K
YoY Change 3.84% -99.44%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.40M $10.40M $16.32M
Total Long-Term Liabilities $20.24M $115.0K $115.0K
Total Liabilities $36.64M $29.37M $35.81M
YoY Change -9.4% -35.9% -18.63%
SHAREHOLDERS EQUITY
Retained Earnings -$163.7M -$168.3M
YoY Change 28.25% 58.31%
Common Stock $474.8M $471.5M
YoY Change 30.47% 118.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $293.3M $311.1M $303.1M
YoY Change
Total Liabilities & Shareholders Equity $329.9M $340.5M $338.9M
YoY Change 22.74% 20.7% 120.33%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$22.54M $4.618M -$15.81M
YoY Change 107.65% -121.66% 76.48%
Depreciation, Depletion And Amortization $405.0K $352.0K $365.0K
YoY Change -10.99% 6.67% 14.06%
Cash From Operating Activities -$14.71M $4.105M -$13.44M
YoY Change 15.12% -127.1% 0.78%
INVESTING ACTIVITIES
Capital Expenditures -$2.849M $2.632M -$3.078M
YoY Change 33.76% 300.0% 755.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Cash From Investing Activities -$2.849M -$2.632M -$3.078M
YoY Change 649.74% -133.56% -124.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 163.0K -1.134M 97.46M
YoY Change -643.33% -100.78% 37385.77%
NET CHANGE
Cash From Operating Activities -14.71M 4.105M -13.44M
Cash From Investing Activities -2.849M -2.632M -3.078M
Cash From Financing Activities 163.0K -1.134M 97.46M
Net Change In Cash -17.39M 339.0K 80.94M
YoY Change 31.91% -99.75% -12947.78%
FREE CASH FLOW
Cash From Operating Activities -$14.71M $4.105M -$13.44M
Capital Expenditures -$2.849M $2.632M -$3.078M
Free Cash Flow -$11.86M $1.473M -$10.37M
YoY Change 11.39% -109.32% -20.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
CY2022Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
CY2022Q1 acet Adjustment To Goodwill
AdjustmentToGoodwill
CY2022Q1 acet Share Based Compensation Arrangement By Share Based Payment Award Options Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
CY2022Q1 acet Proceeds From Sales Of Marketable Debt Securities
ProceedsFromSalesOfMarketableDebtSecurities
CY2022Q1 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001720580
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 acet Taxes Withheld And Paid Related To Net Share Settlement Of Equity Awards
TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-38359
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Adicet Bio, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3305277
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Clarendon Street
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Floor 6
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02116
CY2022Q1 dei City Area Code
CityAreaCode
650
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
503-9095
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
ACET
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40004357
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
277883000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
277544000
CY2022Q1 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
0
CY2021Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
185000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3649000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4709000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
281532000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
282438000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17736000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14643000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19713000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20358000
CY2022Q1 us-gaap Goodwill
Goodwill
19462000
CY2021Q4 us-gaap Goodwill
Goodwill
19462000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1858000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1887000
CY2022Q1 us-gaap Assets
Assets
340451000
CY2021Q4 us-gaap Assets
Assets
338938000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3465000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3263000
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4805000
CY2022Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5203000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6682000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1733000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1567000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
10401000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16317000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18851000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19377000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
115000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
115000
CY2022Q1 us-gaap Liabilities
Liabilities
29367000
CY2021Q4 us-gaap Liabilities
Liabilities
35809000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39885816
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39885816
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39736914
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39736914
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
4000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
474786000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
471449000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-163706000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-168324000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
311084000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
303129000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
340451000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
338938000
CY2022Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
24990000
CY2021Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
-3981000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13483000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11743000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6801000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5630000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
20284000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
17373000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
4706000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-21354000
CY2022Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
32000
CY2021Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
41000
CY2022Q1 us-gaap Interest Expense
InterestExpense
18000
CY2021Q1 us-gaap Interest Expense
InterestExpense
50000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-102000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4618000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21367000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-48000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
4618000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-21319000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.82
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.82
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39823246
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26099954
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45958941
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26099954
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-22000
CY2021Q1 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-22000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4618000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21341000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
303129000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
93000
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1106000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4350000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
4618000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
311084000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
109827000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
976000
CY2021Q1 acet Stock Issued During Period Value Related To Financing
StockIssuedDuringPeriodValueRelatedToFinancing
143754000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3043000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-21319000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-22000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
236259000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
4618000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-21319000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
352000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
326000
CY2022Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
645000
CY2021Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
686000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4350000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3043000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-9000
CY2022Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-18000
CY2022Q1 acet Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
18000
CY2021Q1 acet Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
184000
CY2022Q1 acet Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
0
CY2021Q1 acet Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
460000
CY2022Q1 us-gaap Notes Reduction
NotesReduction
0
CY2021Q1 us-gaap Notes Reduction
NotesReduction
3981000
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
CY2021Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-380000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-185000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1077000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-36000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-117000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
377000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-612000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
196000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4805000
CY2022Q1 acet Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-361000
CY2021Q1 acet Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-438000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1497000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1553000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4105000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15146000
CY2021Q1 acet Proceeds From Sales Of Marketable Debt Securities
ProceedsFromSalesOfMarketableDebtSecurities
7500000
CY2021Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
1000000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2632000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
658000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2632000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7842000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
143754000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
94000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
976000
CY2022Q1 acet Taxes Withheld And Paid Related To Net Share Settlement Of Equity Awards
TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards
-1106000
CY2022Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
122000
CY2021Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
157000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1134000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
144887000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
339000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
137583000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
277694000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88857000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
278033000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
226440000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
277883000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
221667000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4773000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
278033000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
226440000
CY2021Q1 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
158000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1481000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
67000
CY2021Q1 acet Adjustment To Goodwill
AdjustmentToGoodwill
56000
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents. The Company’s cash and cash equivalents are held at two financial institutions in the U.S. and one financial institution in Israel and such amounts may, at times, exceed insured limits. The Company invests its cash equivalents in money market funds. The Company limits its credit risk associated with cash equivalents by placing them with banks and institutions it believes are highly creditworthy and in highly rated investments. The Company has not experienced any losses on its deposits of cash and cash equivalents to date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> customer, Regeneron, which represents all of the Company’s revenue for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> and 2021 (see Note 8).</span></p>
CY2022Q1 acet Number Of Customer
NumberOfCustomer
1
CY2021Q1 acet Number Of Customer
NumberOfCustomer
1
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P60D
CY2020 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
2300000
CY2021Q1 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
500000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
700000
CY2022Q1 us-gaap Prepaid Insurance
PrepaidInsurance
1414000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1021000
CY2022Q1 acet Prepayments To Cros
PrepaymentsToCros
1031000
CY2021Q4 acet Prepayments To Cros
PrepaymentsToCros
1658000
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1128000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
115000
CY2022Q1 acet Prepayments To Cmos
PrepaymentsToCmos
31000
CY2021Q4 acet Prepayments To Cmos
PrepaymentsToCmos
1884000
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
45000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
31000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3649000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4709000
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24372000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
20969000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6636000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6326000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17736000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14643000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2022Q1 acet Increase In Construction In Progress
IncreaseInConstructionInProgress
3300000
CY2022Q1 us-gaap Construction Payable Current And Noncurrent
ConstructionPayableCurrentAndNoncurrent
13800000
CY2022Q1 acet Increase In Construction Budget
IncreaseInConstructionBudget
5300000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2314000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4020000
CY2022Q1 acet Accrued Cmo Costs
AccruedCmoCosts
1617000
CY2021Q4 acet Accrued Cmo Costs
AccruedCmoCosts
1077000
CY2022Q1 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
783000
CY2021Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
546000
CY2022Q1 acet Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
418000
CY2021Q4 acet Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
504000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
53000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
503000
CY2022Q1 acet Accrued Cro Costs
AccruedCroCosts
18000
CY2021Q4 acet Accrued Cro Costs
AccruedCroCosts
32000
CY2022Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5203000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6682000
CY2022Q1 acet Exercised Investment Right And Purchased
ExercisedInvestmentRightAndPurchased
10000000.0
CY2022Q1 acet Contract Assets
ContractAssets
0
CY2021Q1 acet Licence Agreement Cumulative Revenue Recognised
LicenceAgreementCumulativeRevenueRecognised
27000.0
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1007000
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
143000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2022Q1 us-gaap Sublease Income
SubleaseIncome
167000
CY2022Q1 us-gaap Lease Cost
LeaseCost
983000
CY2022Q1 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
511000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y6M
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.071
CY2022Q1 acet Operating Leases Future Minimum Sublease Income Remainder Of Fiscal Year
OperatingLeasesFutureMinimumSubleaseIncomeRemainderOfFiscalYear
493000
CY2022Q1 acet Operating Leases Future Minimum Sublease Income Due Current
OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent
671000
CY2022Q1 acet Operating Leases Future Minimum Sublease Income Due In Two Years
OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears
685000
CY2022Q1 acet Operating Leases Future Minimum Sublease Income Due In Three Years
OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears
699000
CY2022Q1 acet Operating Leases Future Minimum Sublease Income Due In Four Years
OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears
416000
CY2022Q1 acet Operating Leases Future Minimum Sublease Income Due
OperatingLeasesFutureMinimumSubleaseIncomeDue
2964000
CY2022Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
2582000
CY2022Q1 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3428000
CY2022Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3525000
CY2022Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3625000
CY2022Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
13747000
CY2022Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
26907000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6324000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
20583000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1733000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18851000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9667148
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6829205
CY2022Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
220890
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4350000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3043000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3875317
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.08
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M6D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13212000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1555000
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.59
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
10099
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.29
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
44073
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
14.21
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5376145
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.24
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M20D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
30825000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1296481
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13.67
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y5M12D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8174000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5376145
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
14.24
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y10M20D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
30825000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.774
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.777
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.792
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.798
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.016
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.024
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.007
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.009
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
560000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
4618000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21319000
CY2022Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
39823246
CY2021Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
26099954
CY2022Q1 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
5376145000
CY2021Q1 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
0
CY2022Q1 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
538660000
CY2021Q1 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
0
CY2022Q1 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
220890000
CY2021Q1 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
0
CY2022Q1 us-gaap Weighted Average Limited Partnership Units Outstanding Diluted
WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
45958941
CY2021Q1 us-gaap Weighted Average Limited Partnership Units Outstanding Diluted
WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
26099954
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.82
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.82

Files In Submission

Name View Source Status
0000950170-22-009690-index-headers.html Edgar Link pending
0000950170-22-009690-index.html Edgar Link pending
0000950170-22-009690.txt Edgar Link pending
0000950170-22-009690-xbrl.zip Edgar Link pending
acet-20220331.htm Edgar Link pending
acet-20220331.xsd Edgar Link pending
acet-20220331_cal.xml Edgar Link unprocessable
acet-20220331_def.xml Edgar Link unprocessable
acet-20220331_htm.xml Edgar Link completed
acet-20220331_lab.xml Edgar Link unprocessable
acet-20220331_pre.xml Edgar Link unprocessable
acet-ex31_1.htm Edgar Link pending
acet-ex31_2.htm Edgar Link pending
acet-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending